



**Full Length Article**

## Effect of Pioglitazone on Glucose and Glycation Level in Type 2 Diabetic Patients

MUHAMMAD ALIM<sup>1</sup>, RAKHSHANDA NAWAZ, MUHAMMAD RAFIQUE ASI<sup>†</sup>, FAROOQ ANWAR AND TAHIRA IQBAL

*Department of Chemistry and Biochemistry, University of Agriculture, Faisalabad-38040, Pakistan*

<sup>†</sup>*Nuclear Institute for Agriculture and Biology (NIAB), Faisalabad, Pakistan*

Corresponding author's e-mail: prof\_alim68@yahoo.com

### ABSTRACT

To elucidate the effects of pioglitazone treatment on glucose and glycation level in patients with type 2 diabetes, a total of 8 patients were treated with pioglitazone (30 mg day<sup>-1</sup>) for 12 weeks. After this period, there was a significant decrease in fasting plasma glucose and glycation level. The fasting plasma glucose was decreased from 195 to 159 mg per dL and glycation level decreased from 0.140 to 0.113 moles of glucose per moles of protein. These results suggest that pioglitazone decreases fasting plasma glucose in type 2 diabetic patients and acts as an inhibitor of glycation *in-vivo*. © 2010 Friends Science Publishers

**Key Words:** Pioglitazone; Glycation; Diabetic; Inhibitor

### INTRODUCTION

Diabetes mellitus commonly referred to as “diabetes” is a group of metabolic diseases characterized by abnormalities at multiple organ sites. These defects include insulin secretion, insulin action or both (Barnett, 2007). There are different forms of diabetes mellitus but type 2 diabetes is the most common. It is also known as the non-insulin dependent diabetes mellitus (NIDDM) and occurs as a result of progressive insulin secretory defect on the background of insulin resistance (American Diabetes Association, 2009). About 90 to 95% of people suffering from this disease have type 2 diabetes (DeFronzo, 1997).

Without proper management many complications arise under hyperglycemic conditions. A high glucose concentration increases protein glycation, also known as non-enzymatic glycosylation in blood and various organs (Krishnanurti & Steffes, 2001). These non-enzymatic reactions between reducing sugars and free amino groups of proteins can alter the structure and function of proteins (Hartog *et al.*, 2007) and result in the formation of advanced glycation end products (Ulrich & Cerami, 2001).

Pioglitazone (±) 5-{{4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl}-2, 4-thiazolidinedione is an oral anti-hyperglycemic agent, which is used in the treatment of type 2 diabetes (Gillies & Dunn, 2000). It belongs to a class “thiazolidinediones”, represent a potentially important group of drugs with a mechanism of action differing from the existing therapies (Yki-Jarvinen, 2004). It acts primarily by decreasing insulin resistance in the treatment of type 2 diabetes (Radhakrishna *et al.*, 2002). It is a peroxisome proliferator activated receptor (PPAR $\gamma$ ) agonist that

increases transcription of insulin responsive genes and thus increases insulin sensitivity (Scholz *et al.*, 2001).

Most of the drugs metabolizing genes show different activities in different populations, which are often major determinants of variable drug exposure and response (Flockhart & Desta, 2009). Moreover individuals can differ greatly in their inherent capacity to absorb, distribute, excrete and metabolize drugs (Vesell, 1974). To accomplish the clinical benefits, safe and effective drug therapy is difficult due to large inter-patient variability in response to many drugs (Flockhart & Desta, 2009). The values of biochemical and physiological parameters present in the literature are not inline with the values calculated under our own environmental conditions. Therefore for the welfare of humanity it is very necessary to generate information in our population to develop our own therapeutic standards under local environment.

Pioglitazone has been studied rarely and its effect on glycation level has been reported only from few countries. Moreover glycation research remains an area of outstanding interest, fascination and innovation in chemistry, biology, medicine, food, nutrition and applied sciences. Therefore the present project was designed to widen our knowledge about pioglitazone (an anti-diabetic) in Pakistani patients under our own ecological conditions.

### Study Design and Methods

**Subjects:** A total of eight type 2 diabetic patients, clinically diagnosed by physicians, were recruited from the outpatient medicine clinic of the General Hospital Faisalabad, Pakistan. They were recommended diet and exercise at initial stage to control the diabetes. Patients who had previously received insulin, metformin, thiazolidinedione or

any other medicine related to diabetes were excluded. Entry criteria included age (35-55) years and weight (55-85 kg). Patients were in good general health without cardiac, hepatic, renal or other chronic diseases. The demographic and clinical data of the patients is presented in Tables I and II.

**Study design:** The study was conducted for 12 weeks by keeping in view the ethical principles laid down in the Declaration of Helsinki (World Medical Association, 2004). Initially subject's education was updated and their ability to comply with the protocol was checked. The subjects were instructed to take balanced diet during study period. All subjects gave signed, informed consent before participation in the study.

**Plasma collection:** Blood samples from each patient after every 15 days, up to 12 weeks were collected by using sterilize disposable syringes by venopuncture in pre-heparinised centrifuge tubes 10 mL Vacuette® Griener Bio-one, Austria. These samples were mixed gently and were then centrifuge at 4000 rpm and plasma was stored at  $-20^{\circ}\text{C}$ .

**Analysis techniques:** In plasma samples amount of glucose was estimated by Kit method, protein concentration by Biuret method and glycation level by Thiobarbituric acid (TBA) method as described by Furth (1988), spectrophotometrically.

**Statistical analysis:** For computation and the graphics, the Microsoft Excel 7.0 was used. All data are reported as the mean $\pm$ SE (Steel *et al.*, 1997).

## RESULTS

The results illustrating the effect of pioglitazone on glucose concentration, proteins concentration and glycation level in diabetic patients are presented in the Figs. 1–5. In patients, there is regular decrease in the concentration of fasting plasma glucose (FPG). After 8<sup>th</sup> week, minimum concentration ( $159.0\pm 3.30\text{ mg dL}^{-1}$ ) was obtained in comparison to  $195.5\pm 8.65\text{ mg per dL}$  detected at the start of the study. This level slightly increased to  $163.0\pm 4.64\text{ mg per dL}$  after 10<sup>th</sup> week and then declined to  $159.38\pm 4.65\text{ mg per dL}$  (Fig. 1). There is not gradual increase or decrease in the concentration of plasma proteins. These values changed randomly and maximum concentration  $67.96\pm 1.77\text{ mg per mL}$  was achieved after 6<sup>th</sup> week and minimum value  $65.83\pm 1.93\text{ mg per mL}$  after 10<sup>th</sup> week (Fig. 2).


In patients, long term therapy with pioglitazone significantly decreased the glycation level. This level reduced gradually up to 12<sup>th</sup> week, but in last weeks value of glycation level become consistent. Maximum glycation level ( $0.144\pm 0.014\text{ mole mole}^{-1}$ ) was observed after 2<sup>nd</sup> week and minimum value  $0.113\pm 0.010\text{ mole per mole}$  was obtained after 12<sup>th</sup> week (Fig. 3). The trends between the change in fasting plasma glucose and glycation level and the change in concentration of proteins and glycation level are shown in Figs. 4 and 5, respectively.

**Table I: Demographic data of diabetic patients**


Subject	Age	Weight	Height	Blood Pressure		Body	BMI*	
No.	ID	Years	Kg	Inches	Systolic	Diastolic	°F	Kg/m <sup>2</sup>
1	A <sub>p</sub>	42	74	66	134	82	98.5	25.62
2	B <sub>p</sub>	45	68	58	130	72	97.8	31.33
3	C <sub>p</sub>	49	82	66	140	85	99.2	29.18
4	D <sub>p</sub>	38	71	59	124	78	98.2	31.61
5	E <sub>p</sub>	53	80	67	129	84	98.4	26.24
6	F <sub>p</sub>	50	81	60	136	90	98.5	34.87
7	G <sub>p</sub>	43	76	62	126	86	98.7	30.65
8	H <sub>p</sub>	36	70	63	122	84	98	27.34
Mean		44.5	75.25	62.63	130.125	82.625	98.4	29.61
$\pm$ SE		2.24	2.02	1.31	2.34	2.07	0.16	1.18

Subscript 'P' stands for patient, \*BMI is Body Mass Index

**Fig. 1: Change in concentration of glucose in diabetic patients**



**Fig. 2: Change in concentration of plasma proteins in diabetic patients**



## DISCUSSION

Results indicate that long term therapy with pioglitazone have significant effect on FPG level in type 2 diabetic patients. This effect is more pronounced up to 8<sup>th</sup> week then concentration become almost constant. These results are similar to the results reported in the literature. Pioglitazone decrease blood glucose in diabetic animal models (Saltiel & Olefsky, 1996) and in patients with type 2 diabetes (Suter *et al.*, 1992). In general decrease in plasma glucose or improvement of insulin resistance by pioglitazone requires several days in diabetic animals




**Table II: Clinical data of diabetic patients in the fasting state**

Subject No.	ID	Glucose mg dL <sup>-1</sup>	Serum creatinine mg dL <sup>-1</sup>	Triglycerides mg dL <sup>-1</sup>	Hb g dL <sup>-1</sup>	Cholesterol mg dL <sup>-1</sup>	SGPT UL <sup>-1</sup>	Total protein g dL <sup>-1</sup>	TLC /cmm	Neutrophils %	Lymphocytes %
1	A <sub>p</sub>	192	0.7	125	13.5	174	30	7.2	7900	59	32
2	B <sub>p</sub>	202	0.8	118	12.9	230	26	6.2	6500	57	36
3	C <sub>p</sub>	224	0.5	235	13	192	35	6.5	8200	65	30
4	D <sub>p</sub>	168	0.9	128	12.4	234	18	6.1	10100	58	35
5	E <sub>p</sub>	182	1.1	171	11.4	160	41	6.2	7600	62	34
6	F <sub>p</sub>	229	0.6	237	14.2	184	29	6.3	9200	57	32
7	G <sub>p</sub>	157	1.0	323	15.1	142	21	6.6	9800	64	28
8	H <sub>p</sub>	199	0.8	128	13.4	265	26	7.3	8700	60	34
Mean		194.1	0.8	183.1	13.2	197.6	28.3	6.6	8500	60.3	32.6
± SE		9.5	0.1	28.2	0.4	15.8	2.8	0.2	451.9	1.2	1.0

Subscript 'P' stands for patient, Hb: hemoglobin, SGPT: Serum Glutamic-Pyruvic Transaminase, TLC: Total leucocyte count

(Saltiel & Olefsky, 1996) or several weeks in patients with type 2 diabetes (Iwamoto *et al.*, 1991; Suter *et al.*, 1992). Aronoff *et al.* (2000) mentioned that the blood glucose lowering effect of pioglitazone developed gradually over weeks and maximum decrease was observed after 10-14 weeks. Pioglitazone have the ability to reduce both fasting and postprandial glucose levels (Suter *et al.*, 1992; Ravikumar *et al.*, 2008). After pioglitazone treatment, fasting and postprandial endogenous glucose production (EGP) decreased ( $16.6 \pm 1.0$  vs.  $12.2 \pm 0.7$   $\mu\text{mol kg}^{-1} \text{min}^{-1}$ ) and ( $2.58 \pm 0.25$  vs.  $1.26 \pm 0.30$   $\mu\text{mol/Kg/min}$ ), respectively (Ravikumar *et al.*, 2008). Rubin *et al.* (1999) also observed a decrease in FBG levels of up to 60 mg/dL in a combination therapy. The results about the analysis of plasma proteins illustrate that there is not regular increase or decrease in the concentration of proteins. These values remain within the normal limits. This indicate that long term treatment with pioglitazone have no effect on plasma proteins in type 2 diabetic patients.

The decrease in the glycation level after 12 weeks treatment with pioglitazone is not surprising, because similar results are available in previous literature. As the pioglitazone significantly improves the glycemic control (Pavo *et al.*, 2003; Umpierrez *et al.*, 2006), therefore its inhibitory effect on glycation process can be explained in this scenario. As monotherapy, it improves the fasting blood glucose and glycosylated hemoglobin (Stratton *et al.*, 2000; Pavo *et al.*, 2003). On average, fasting blood glucose and glycosylated hemoglobin can be improved by approximately 40 mg per dL and almost 1%, respectively (Stumvoll & Haring, 2002). It was effective in reducing plasma glucose from the baseline levels from week 4 and this decrease continued up to the last measurement at week 12 (Abe *et al.*, 2007). In Wistar fatty rats, GHb levels declined gradually over 5 weeks administration of pioglitazone (Nagisa *et al.*, 2003). It also acts as an important inhibitor of glycation and potent antioxidant (Rahbar *et al.*, 2000; Gumieniczek, 2005). Moreover the pattern between the change in FPG and glycation level is quite similar, they show almost similar trends during the study. The pattern between change in concentration of proteins and glycation level in patients demonstrate that trend in the concentration change of plasma proteins is not similar to change in glycation level.

**Fig. 3: Change in Glycation level in diabetic patients****Fig. 4: Pattern between glycation level and concentration of glucose in diabetic Patients****Fig. 5: Pattern between glycation level and concentration of proteins in diabetic patients**

## CONCLUSION

Pioglitazone decreases the fasting plasma glucose level and acts as an inhibitor of glycation in type 2 diabetes patients.

**Acknowledgement:** We acknowledge the support provided by the University of Agriculture, Faisalabad, Pakistan, in terms of equipment and laboratory facilities. Moreover we are grateful to the Higher Education Commission (HEC), Islamabad, Pakistan for finance of this research.

## REFERENCES

- Abe, M., F. Kikuchi, K. Kaizu and K. Matsumoto, 2007. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2 diabetic patients on hemodialysis. *Clin. Nephrol.*, 68: 287–294
- American Diabetes Association, 2009. Standards of medical care in diabetes. *Diabetes Care*, 32: S13–S61
- Aronoff, S., S. Rosenblatt, S. Braithwaite, J.W. Egan, A.L. Mathisen and R.L. Schneider, 2000. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6 month randomized placebo-controlled dose-response study. *Diabetes Care*, 23: 1605–1611
- Barnett, A.H., 2007. Summarising the use of thiazolidinediones with insulin. *British J. Diabetes Vasc. Dis.*, 7: 75–80
- DeFronzo, R.A., 1997. Pathogenesis of type 2 diabetes: Metabolic and molecular implication for identifying diabetes genes. *Diabetes Rev.*, 5: 177–267
- Flockhart, D.A. and Z. Desta, 2009. *Pharmacogenetics of Drug Metabolism*, pp: 301–317. Clinical and Translational Science
- Furth, A.J., 1988. Methods for assaying non-enzymatic glycosylation: A review. *Annal. Biochem.*, 175: 347–360
- Gillies, P.S. and C.J. Dunn, 2000. Pioglitazone. *Drugs*, 60: 333–343
- Gumieniczek, A., 2005. Effects of pioglitazone on hyperglycemia induced alterations in antioxidative system in tissues of alloxan-treated diabetic animals. *Exp. Toxicol. Pathol.*, 56: 321–326
- Hartog, J.W.L., A.A. Voors, S.J.L. Bakker, A.J. Smit and D.J. Veldhuisen, 2007. Advanced glycation end products (AGEs) and heart failure: Pathophysiology and clinical implications. *European J. Heart Failure*, 9: 1146–1155
- Iwamoto, Y., T. Kuzuya, A. Matsuda, T. Awata, S. Kumakura, G. Inooka and I. Shiraishi, 1991. Effect of a new oral anti-diabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. *Diabetes Care*, 14: 1083–1086
- Krishnanurti, U. and M.W. Steffes, 2001. Glycohemoglobin: A primary predictor of the development or reversal of complications of diabetes mellitus. *Clin. Chem.*, 47: 1157–1165
- Nagisa, Y., K. Kato, K. Watanabe, H. Murakoshi, H. Odaka, K. Yoshikawa and Y. Sugiyama, 2003. Changes in glycated hemoglobin levels in diabetic rats measured with an automatic affinity HPLC. *Clin. Exp. Pharmacol. Physiol.*, 30: 752–758
- Pavo, I., G. Jermendy, T.T. Varkonyi, Z. Kerenyi, A. Gyimesi, S. Shoustov, M. Shestakova, M. Herz, D. Johns, B.J. Schluchter, A. Festa and M. Tan, 2003. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. *J. Clin. Endocrinol. Metab.*, 88: 1637–1645
- Radhakrishna, T., D.R. Sreenivas and G.O. Reddy, 2002. Determination of pioglitazone hydrochloride in bulk and pharmaceutical formulations by HPLC and MEKC methods. *J. Pharm. Biomed. Anal.*, 29: 593–607
- Rahbar, S., R. Natarajana, K.K. Yernenia, S. Scott, N. Gonzales and J.L. Nadler, 2000. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. *Clinica Chimica Acta.*, 301: 65–77
- Ravikumar, B., J. Gerrard, C.D. Man, M.J. Firbank, A. Lane, P.T. English, C. Cobelli and R. Taylor, 2008. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. *Diabetes*, 57: 2288–2295
- Rubin, C., J. Egan and R. Schneider, 1999. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes. *Diabetes*, 48: A110
- Saltiel, A.R. and J.M. Olefsky, 1996. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. *Diabetes*, 45: 1661–1669
- Scholz, G.H., W.A. Scherbaum and G. Lubben, 2001. Pioglitazone a review of preclinical data. *Diabetes Stoffwechsel*, 9: 23–30
- Steel, R.G.D., J.H. Torrie and D.A. Dickey, 1997. *Principles and Procedures of Statistics: A Biometrical Approach*. Mc Graw Hill Book Co., Inc., New York
- Stratton, I.M., A.I. Adler, H.A. Neil, D.R. Matthews, S.E. Manley, C.A. Cull, D. Hadden, R.C. Turner and R.R. Holman, 2000. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. *BMJ*, 321: 405–412
- Stumvoll, M. and H.U. Haring, 2002. Glitazones: Clinical effects and molecular mechanisms. *Annl. Med.*, 34: 217–224
- Suter, S.L., J.J. Nolan, P. Wallace, B. Gumbiner and J.M. Olefsky, 1992. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. *Diabetes Care*, 15: 193–203
- Ulrich, P. and A. Cerami, 2001. Protein glycation, diabetes and aging. *Recent. Prog. Horm. Res.*, 56: 1–21
- Umpierrez, G., M. Issa and A. Vlahjnic, 2006. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. *Curr. Med. Res. Opin.*, 22: 751–759
- Vesell, E.S., 1974. Relationship between drug distribution and therapeutic effects in man. *Annu. Rev. Pharmacol.*, 14: 249–270
- World Medical Association, 2004. *Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects*. 55<sup>th</sup> WMA; General Assembly, Tokyo, Japan
- Yki-Jarvinen, H., 2004. Thiazolidinediones. *N. England J. Med.*, 351: 1106–1118

(Received 26 September 2009; Accepted 10 October 2009)